Mumbai, India-based Torrent Pharmaceuticals has launched a division focusing on diabetes products, according to Reuters, which noted that the AzuCa division will begin operations in April, with an initial sales force of 300. Setting up the division should boost the company's market share in the sector to 15%-20% within three years from the current 2%, according to the company's vice president of marketing, Sujesh Vasudevan. Torrent's existing diabetes products - including Betacard AM, Enselin, Tozaar R and Migtor
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze